Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in c-MET or RON-Positive Metastatic Urothelial Cancer
NCT02612194Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Sep 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crizotinib in urothelial carcinoma (UC), sponsored by Wake Forest University Health Sciences. Started Sep 2016; status: terminated.
02
Drugs
crizotinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02612194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612194.